A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
Latest Information Update: 13 Jun 2025
At a glance
- Drugs Mavorixafor (Primary) ; Granulocyte colony-stimulating factors
- Indications Neutropenia
- Focus Registrational; Therapeutic Use
- Acronyms 4WARD
- Sponsors X4 Pharmaceuticals
Most Recent Events
- 10 Jun 2025 According to a X4 Pharmaceuticals media release, potential top-line data from this study expected in late 2026.
- 14 May 2025 According to a X4 Pharmaceuticals media release, based on Phase 2 trial results as supportive of the design of the Phase 3 trial and a signal of its potential for success.
- 01 May 2025 According to a X4 Pharmaceuticals media release, the company recently applied the 4WARD trial ANC response criteria to individual participant results in the completed mavorixafor Phase 3 4WHIM trial and the Phase 2 CN trial to further assess the likelihood of 4WARD trial success.